|
Author |
Date and source |
Quotes |
|
|
|
|
Harvey Bale, International Federation of Pharmaceutical
Manufacturers Associations |
26 March 2003 Financial Times |
There is a big risk here. If companies feel they will not
make a sufficient return on developing AIDS drugs, one day they
will decide not to do the research. |
| Ram
Etwareea |
25/26
August 2001
Le
Temps
|
"
L'accord (TRIPS) établit un équilibre entre, d'une part, la
protection de la propriété intelectuelle - fondamentale si
l'on veut que de nouveaux médicaments soient mis au point -
et, d'autre part, la fléxibilité qui doit être ménagée
aux pays afin que les populations les plus pauvres puissent
accéder aux médicaments" |
| Indian
Prime Minister, A.B. Vajpayee |
21
August 2001
The
Hindu
(quoting
Mr. Vajpayee)
|
"
First,
he felt there should be no misappropriation of the biological
and genetic resources and traditional knowledge of the
developing countries. It was thus necessary to mandate that
patent applications revealed the country of origin of such
resources and traditional knowledge used in the product or
process for which the patent was sought. " |
| Ambassador
of Zimbabwe, Boniface Chidyausiku |
22
June 2001
WTO
Press Release
|
"
I think I can safely say that all members are determined to
ensure that the TRIPS Agreement is part of the solution and
not part of the problem of meeting the public health crises in
poor countries. That includes the HIV/AIDS crisis in my own
continent of Africa, but HIV/AIDs is by no means the only
problem." |
| WTO
Director-General, Mike Moore |
22
June 2001
WTO
Press Release
|
"
The crisis of disease facing developing countries is dire.
Every year malaria, tuberculosis and HIV/AIDS kill around 6
million people, almost all of them in the developing world. As
I have said before, these premature deaths are a reproach to
us all. They are also a huge blow to countries’ hopes for
development. Urgently, more needs to be done to save the lives
of millions of poor people…The WTO’s TRIPS Agreement plays
a vital role in tackling these problems. It strikes a
carefully-negotiated balance between providing intellectual
property protection — which is essential if new medicines
and treatments are to be developed — and allowing countries
the flexibility to ensure that treatments reach the world’s
poorest and most vulnerable people." |
| |
|
|
| |
|
|
| |
|
|
Home
TRADE RESOURCES
